Innogen · Publications · Journal articles
Editorial: Public Health Pharmacogenomics and the Design Principles for Global Public Goods – Moving Genomics to Responsible Innovation
Current Pharmacogenomics and Personalized Medicine 11 (1) 1-4
Genomics and development, genomics without borders, global governance of biotechnology innovation and uncertainty, P5 medicine, public health pharmacogenomics, responsible innovation, STS and organizations, theranostic medicine.
“Evidence in the clinical care context differs from evidence in the public health and health policy domains. It is often difficult to apply rigid hierarchies of evidence to public health policy.”
“Pharmacogenomics and personalized medicine knowledge cannot be siloed into a pure and narrow technology lens alone. The field’s ontology requires a nuanced understanding of the complex linkages between the science, technology, society, and politics ecosystem and therefore must be situated within a broader framework.”
Edward S. Dove
“The trend has been to use data derived from African populations to build research programmes and enhance individual careers in more affluent communities with little or no consideration for the populations from which this material was derived.”
Jantina de Vries and Michael Pepper
Current Pharmacogenomics and Personalized Medicine (CPPM) was launched in 2008 to respond to knowledge, policy and biotechnology governance gaps at the unique intersection of personalized medicine, genomics, public health and social studies of knowledge-based innovation. Distinct from traditional discovery science characterized by a “first hypothesize-then-experiment” method of scientific inquiry, this nascent field of public health pharmacogenomics is richly informed by CPPM scholarship that recognizes the new dual reconfiguration of 21st-century data-intensive omics science, blending infrastructure science and discovery science. Importantly, CPPM addresses novel diagnostics and responsible personalized medicine applications both in developing and developed countries. This is crucial for global capacity building, as developing countries may lack the resources, expertise and sound regulation for pharmacogenomics; this may result in premature buy-in for novel biotechnologies without adequate alignment with local public health priorities and societal values.
The journal aims to strike the right balance to catalyze the transition of pharmacogenomics and personalized medicine discoveries to practice, while preventing the premature translation of candidate applications. Finally, the journal integrates molecular and clinical investigation with public policy and social studies of biotechnology, which collectively shape the postgenomics personalized medicine innovation trajectory.